Treatment response and clinical outcomes of well differentiated high grade neuroendocrine tumors to lutetium-177 DOTATATE

Conclusion: We observed a meaningful disease control rate of 72% during treatment of WD HG NETs with 177Lu-DOTATATE. In this heavily pre-treated population, more than half of patients received all four treatment cycles with toxicities largely bone-marrow related. As would be expected in WD NETs, the vast majority had alterations in chromatin remodeling genes and no RB1 alterations.
Source: Neuroendocrinology - Category: Endocrinology Source Type: research